NovaGray is a brand that focuses on personalized medicine to support patients with breast and prostate cancer. Their mission is to enhance the individualized management of patients by offering innovative solutions. NovaGray aims to provide reassurance to patients before beginning radiotherapy, assist physicians in selecting the most suitable treatment plan, and facilitate follow-up care after radiotherapy.

The team at NovaGray is led by Clemence Franc, the Chief Executive Officer and Co-founder. Clemence brings together a highly skilled team to help fulfill the vision of personalized medicine. Recognized as a Top 10 French Innovator Under 35 by MIT Technological Review in 2017, her expertise is invaluable to the brand.

Dr. David Azria, the Co-founder and Chief Medical Officer, is a professor in radiation oncology with a PhD in radiobiology. He leads the Department of Radiation Oncology at the Montpellier Cancer Institute and contributes significantly to clinical trials in France and internationally.

Dr. Azria has been recognized for his contributions to the field, including the Translational Science Abstract Award at the American Society for Radiation Oncology (ASTRO) Annual Meeting. Dr.

Muriel Brengues, the Chief Scientific Officer, is an expert in ionizing radiation. With a background in biochemistry and cellular biology, she has extensive experience in the field. Previously working in the USA for 10 years, Dr.

Brengues is currently part of Dr. Azria's research team and has also conducted research at the National Center for Scientific Research (CNRS) in France. NovaGray offers innovative solutions and a dedicated team that is committed to providing personalized care for patients with breast and prostate cancer